.png)
How Much Could Your Organization Save On GLP-1 And Metabolic Health Benefit Costs?
How Much Could Your Organization Save On GLP-1 And Metabolic Health Benefit Costs?
Large employers face a growing and largely unmanaged GLP-1 cost crisis. Health Dividend 360 is designed to deliver meaningful, measurable savings — through wholesale drug pricing, downstream medical cost avoidance, and a voluntary benefit structure that limits employer liability. Model your organization's opportunity below.
Model Your Organization's Savings Opportunity
Select Your Employee Population
Estimates based on conservative industry assumptions. Actual results vary by workforce demographics, enrollment rates, and plan design.
Four Mechanisms That Drive Measurable Employer Savings
Wholesale Drug Pricing
Health Dividend 360 provides access to GLP-1 and metabolic-health medications at wholesale pricing — delivering up to 68% savings versus retail pharmacy costs for the same FDA-approved medications.
Downstream Medical Cost Avoidance
Effective metabolic-health management reduces downstream medical utilization — fewer ER visits, hospitalizations, and comorbidity-related claims. Participants generate measurable medical cost avoidance over time.
Voluntary Benefit Structure
Because HD360 is a voluntary benefit funded through employee payroll deduction, the employer's direct cost exposure is limited to the program administration fee — not the full cost of medications.
eMHI-Tracked Population Outcomes
The employer Metabolic Health Index (eMHI) provides longitudinal population-level data that supports benefit strategy decisions, demonstrates program ROI, and enables proactive cost management.
The Cost Of Doing Nothing Is Growing Every Year
Without Health Dividend 360
- GLP-1 medications at full retail pricing ($12,000–$18,000/employee/year)
- Open-ended medical plan liability with no utilization management framework
- No structured measurement of metabolic health outcomes at the population level
- Employee dissatisfaction from lack of access to modern obesity-care options
- Growing year-over-year cost trajectory with no mechanism to bend the curve
With Health Dividend 360
- GLP-1 medications at wholesale pricing — up to 68% below retail
- Voluntary benefit structure limits employer direct cost exposure
- eMHI population reporting provides longitudinal outcomes data and ROI evidence
- Employees gain access to FDA-approved treatment and clinical support
- Measurable downstream medical cost avoidance as metabolic health improves
Ready To See A Precise Savings Model For Your Organization?
The estimator above uses conservative industry assumptions. A strategy call with the Health Dividend 360 team will produce a custom savings model based on your actual employee population, current plan design, and GLP-1 utilization data.